Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase NA 3Phase 1 2Phase 4 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2NET 1Endocrine 1

Conditions

Liver Neoplasms 2Neuroendocrine Tumors 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 223Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Sirtuins × Clear all
NCT01469572 2018-10-18

Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases

Emory University

Phase 1 Completed
13 enrolled
EndocrineGastrointestinalNET

Liver Neoplasms, Neuroendocrine Tumors

NCT00604409 2015-09-07

Study of Capecitabine in Combination With SIR-Spheres in Patients With Advanced Cancer

Fox Chase Cancer Center

Phase 1 Completed
34 enrolled
Gastrointestinal

Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡